Search for: "ACTAVIS"
Results 581 - 600
of 1,012
Sort by Relevance
|
Sort by Date
16 May 2014, 8:58 am
So this moggy is enormously grateful to his EIP colleague Matthew Jones, for preparing a report of this case, which came out at the same time as the Actavis v Lilly decision. [read post]
15 May 2014, 11:40 am
Although the claims also required other components, Actavis admitted that the product is to be administered in combination with vitamin B12 and folic acid (since Actavis intend to seek regulatory approval by reference to Lilly's product which is administered together with both vitamin B12 and folic acid), and so the infringement of other integers of the claim was not at issue. [read post]
13 May 2014, 2:50 pm
First, the Actavis decision is not limited to cash. [read post]
13 May 2014, 2:50 pm
First, the Actavis decision is not limited to cash. [read post]
13 May 2014, 9:23 am
"All this is compliant with the GAT and Folien decisions and the Corte di Cassazione ruling, as well the UK decision in Joined cases Actavis Group hf v Eli Lilly & Company (USA) and Medis ehf v Eli Lilly & Company (USA) [here]. [read post]
13 May 2014, 5:00 am
Actavis plc (NYSE: ACT) announced yesterday that it has entered into an agreement with Valeant Pharmaceuticals International (NYSE: VRX) to settle all outstanding patent litigation related to Actavis' generic version of Acanya®... [read post]
13 May 2014, 5:00 am
Actavis plc (NYSE: ACT) announced yesterday that it has entered into an agreement with Valeant Pharmaceuticals International (NYSE: VRX) to settle all outstanding patent litigation related to Actavis' generic version of Acanya®... [read post]
9 May 2014, 8:14 am
Actavis South Atlantic LLC, et al., Consol. [read post]
5 May 2014, 8:28 am
The launch of Actavis’ product is contingent upon Actavis receiving final approval from the U.S. [read post]
2 May 2014, 9:43 am
The FTC brief explains that the no-authorized-generic (no-AG) commitment at issue raises the same antitrust concern that the Supreme Court identified in Actavis. [read post]
2 May 2014, 9:43 am
The FTC brief explains that the no-authorized-generic (no-AG) commitment at issue raises the same antitrust concern that the Supreme Court identified in Actavis. [read post]
2 May 2014, 5:00 am
Supreme Court Denies Teva's Request for an Injunction Relating to Generic Copaxone® --- Actavis Announces Celebrex® Patent Challenge Settlement --- Actavis Net Revenue Increases 40% to $2.66 Billion in First Quarter 2014. [read post]
2 May 2014, 5:00 am
Supreme Court Denies Teva's Request for an Injunction Relating to Generic Copaxone® --- Actavis Announces Celebrex® Patent Challenge Settlement --- Actavis Net Revenue Increases 40% to $2.66 Billion in First Quarter 2014. [read post]
25 Apr 2014, 1:45 am
"Wim van der Eijk observing howmuch the EPO empire has grownIPKat readers will note that Mr Justice Arnold has followed suit in his recent referrals, the Actavis v Sanofi judgment being one such instance. [read post]
22 Apr 2014, 4:51 pm
Wesley Davis, from New York filed a stroke product liability lawsuit against Actavis and Watson. [read post]
16 Apr 2014, 5:35 am
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Researchers have long suspected a link between testosterone treatment and the risk of heart attack, though millions of men who have been taking the hormonal treatments are just now learning of the… [read post]
11 Apr 2014, 7:15 am
Actavis Elizabeth LLC, 2-12-cv-05311 (NJD April 9, 2014, Order) (Linares, J.) [read post]
10 Apr 2014, 12:00 am
Actavis, the Supreme Court held that a brand firm's payment to a... [read post]
8 Apr 2014, 9:59 pm
Actavis, Inc. and Endo Pharmaceuticals Inc. v. [read post]
7 Apr 2014, 8:53 pm
Here is the complete agenda: On the 30th Anniversary of the Drug Price Competition and Patent Term Restoration Act: Understanding Hatch-Waxman's Transformative Impact on the Pharmaceutical Industry Assessing Pharmaceutical Patent Sustainability and Vulnerability: Strategies and Considerations for Brand Names and Generics in Anticipating, Identifying and Determining Which Patents Will be Ripe for Challenges of Invalidity and Non-Infringement Use of IPR and Other PTO Proceedings in a Paragraph… [read post]
